[1] M.J. Antonio, A. Le, Different Tumor Microenvironments Lead to Different Metabolic Phenotypes, Advances in experimental medicine and biology, 1063 (2018) 119-129.
[2] A. Muir, L.V. Danai, M.G. Vander Heiden, Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies, Disease models & mechanisms, 11 (2018).
[3] P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, C.J. De Saedeleer, K.M. Kennedy, C. Diepart, B.F. Jordan, M.J. Kelley, B. Gallez, M.L. Wahl, O. Feron, M.W. Dewhirst, Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice, The Journal of clinical investigation, 118 (2008) 3930-3942.
[4] A.S. Gross, M. Graef, Mechanisms of Autophagy in Metabolic Stress Response, Journal of Molecular Biology, 432 (2020) 28-52.
[5] Y. Hoshida, B.C. Fuchs, K.K. Tanabe, Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges, Current cancer drug targets, 12 (2012) 1129-1159.
[6] P.J. Zamor, A.S. deLemos, M.W. Russo, Viral hepatitis and hepatocellular carcinoma: etiology and management, Journal of gastrointestinal oncology, 8 (2017) 229-242.
[7] S. Fu, R.R. Zhou, N. Li, Y. Huang, X.G. Fan, Hepatitis B virus X protein in liver tumor microenvironment, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37 (2016) 15371-15381.
[8] X.D. Zhang, Y. Wang, L.H. Ye, Hepatitis B virus X protein accelerates the development of hepatoma, Cancer biology & medicine, 11 (2014) 182-190.
[9] X.Y. Huang, D. Li, Z.X. Chen, Y.H. Huang, W.Y. Gao, B.Y. Zheng, X.Z. Wang, Hepatitis B Virus X protein elevates Parkin-mediated mitophagy through Lon Peptidase in starvation, Experimental cell research, 368 (2018) 75-83.
[10] X.-Y. Huang, X.-Z. Wang, Su1504 – Hepatitis B Virus X Protein Exhibits Different Roles on Hepatocellular Carcinoma Metastasis with Varied Nutrient Conditions, Gastroenterology, 156 (2019) S-1287-S-1288.
[11] K. Freese, T. Seitz, P. Dietrich, S.M.L. Lee, W.E. Thasler, A. Bosserhoff, C. Hellerbrand, Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro, Cancers, 11 (2019).
[12] T. Qiu, L. Zhou, W. Zhu, T. Wang, J. Wang, Y. Shu, P. Liu, Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials, Future oncology (London, England), 9 (2013) 255-269.
[13] S. Shin, M. Kim, S.J. Lee, K.S. Park, C.H. Lee, Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes, Cancer genomics & proteomics, 14 (2017) 349-362.
[14] A. Taddei, D. Roche, W.A. Bickmore, G. Almouzni, The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?, EMBO reports, 6 (2005) 520-524.
[15] K.F. Tóth, T.A. Knoch, M. Wachsmuth, M. Frank-Stöhr, M. Stöhr, C.P. Bacher, G. Müller, K. Rippe, Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin, Journal of cell science, 117 (2004) 4277-4287.
[16] B.N. Singh, G. Zhang, Y.L. Hwa, J. Li, S.C. Dowdy, S.W. Jiang, Nonhistone protein acetylation as cancer therapy targets, Expert review of anticancer therapy, 10 (2010) 935-954.
[17] K. Matsubara, A.R. Lee, S. Kishigami, A. Ito, K. Matsumoto, H. Chi, N. Nishino, M. Yoshida, Y. Hosoi, Dynamics and regulation of lysine-acetylation during one-cell stage mouse embryos, Biochemical and biophysical research communications, 434 (2013) 1-7.
[18] M. Mottamal, S. Zheng, T.L. Huang, G. Wang, Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules (Basel, Switzerland), 20 (2015) 3898-3941.
[19] S.G. Gray, S. Kytola, W.O. Lui, C. Larsson, T.J. Ekstrom, Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma, Int J Mol Med, 5 (2000) 33-74.
[20] A. Vassilopoulos, J.D. Pennington, T. Andresson, D.M. Rees, A.D. Bosley, I.M. Fearnley, A. Ham, C.R. Flynn, S. Hill, K.L. Rose, H.S. Kim, C.X. Deng, J.E. Walker, D. Gius, SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient- and exercise-induced stress, Antioxidants & redox signaling, 21 (2014) 551-564.
[21] J.M. Marcus, S.A. Andrabi, SIRT3 Regulation Under Cellular Stress: Making Sense of the Ups and Downs, 12 (2018).
[22] Y. Liu, Y.L. Liu, W. Cheng, X.M. Yin, B. Jiang, The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects, European review for medical and pharmacological sciences, 21 (2017) 978-998.
[23] X. Zeng, N. Wang, H. Zhai, R. Wang, J. Wu, W. Pu, SIRT3 functions as a tumor suppressor in hepatocellular carcinoma, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 39 (2017) 1010428317691178.
[24] A. Mogal, S.A. Abdulkadir, Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes, Molecular and Cellular Probes, 20 (2006) 81-86.
[25] M.V. Blagosklonny, R. Robey, D.L. Sackett, L. Du, F. Traganos, Z. Darzynkiewicz, T. Fojo, S.E. Bates, Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity, Molecular cancer therapeutics, 1 (2002) 937-941.
[26] S. Kwon, S. Seok, P. Yau, X. Li, B. Kemper, J.K. Kemper, Obesity and aging diminish sirtuin 1 (SIRT1)-mediated deacetylation of SIRT3, leading to hyperacetylation and decreased activity and stability of SIRT3, The Journal of biological chemistry, 292 (2017) 17312-17323.
[27] I. Lurje, Z. Czigany, J. Bednarsch, C. Roderburg, P. Isfort, U.P. Neumann, G. Lurje, Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach, International journal of molecular sciences, 20 (2019).
[28] M. Le Grazie, M.R. Biagini, M. Tarocchi, S. Polvani, A. Galli, Chemotherapy for hepatocellular carcinoma: The present and the future, World journal of hepatology, 9 (2017) 907-920.
[29] M. Levrero, J. Zucman-Rossi, Mechanisms of HBV-induced hepatocellular carcinoma, Journal of hepatology, 64 (2016) S84-s101.
[30] P.J. Chen, C. Huang, X.M. Meng, J. Li, Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis, Biochimie, 116 (2015) 61-69.
[31] T. Niki, K. Rombouts, P. De Bleser, K. De Smet, V. Rogiers, D. Schuppan, M. Yoshida, G. Gabbiani, A. Geerts, A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture, Hepatology (Baltimore, Md.), 29 (1999) 858-867.
[32] J.M. O'Rourke, V.M. Sagar, T. Shah, S. Shetty, Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer, World journal of gastroenterology, 24 (2018) 4436-4447.
[33] M. Mrakovcic, J. Kleinheinz, L.F. Fröhlich, Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53, International journal of molecular sciences, 18 (2017).
[34] A. Ansari, M.S. Rahman, S.K. Saha, F.K. Saikot, A. Deep, K.H. Kim, Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease, Aging cell, 16 (2017) 4-16.
[35] J.M. Marcus, S.A. Andrabi, SIRT3 Regulation Under Cellular Stress: Making Sense of the Ups and Downs, Frontiers in neuroscience, 12 (2018) 799.
[36] T. Ren, H. Zhang, J. Wang, J. Zhu, M. Jin, Y. Wu, X. Guo, L. Ji, Q. Huang, H. Zhang, H. Yang, J. Xing, MCU-dependent mitochondrial Ca(2+) inhibits NAD(+)/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells, Oncogene, 36 (2017) 5897-5909.
[37] S. De Matteis, A.M. Granato, R. Napolitano, C. Molinari, M. Valgiusti, D. Santini, F.G. Foschi, G. Ercolani, U. Vespasiani Gentilucci, L. Faloppi, M. Scartozzi, G.L. Frassineti, A. Casadei Gardini, Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma, Digestive Diseases and Sciences, 62 (2017) 1872-1880.